ArticleInternational urogynecology journal2026
Longitudinal Impact of Methenamine Hippurate on the Urobiome of Postmenopausal Women With Recurrent UTIs.
Article in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introduction and hypothesisPostmenopausal women with recurrent urinary tract infections (RUTI) are repeatedly exposed to antibiotics; therefore, they are at risk for colonization by multi-drug resistant organisms. Methenamine hippurate (MH), an antibiotic alternative, has shown clinical promise in preventing RUTI; its activity is traditionally attributed to formaldehyde production, though the precise mechanism of action remains uncertain. We hypothesize that MH administration alters the urobiomes of women with RUTI.
methodsWe conducted a longitudinal study of postmenopausal women with a clinical history of RUTI, evaluating their urobiomes for 3 months. Expanded quantitative urine culture (EQUC) assessed diversity and urobiome composition of catheterized urine, voided urine, and peri-urethral swabs; 16S rRNA gene sequencing determined taxonomic classification, beta diversity, and differential abundance analysis of voided urine only.
resultsNo UTIs occurred for any participant. Instead, we observed improvement in symptoms. EQUC and 16S sequencing revealed predominance of Enterobacteriaceae, especially E. coli, and members of several Gram-positive genera, including emerging uropathogens. Following MH therapy initiation, diversity of catheterized urine specimens increased and voided urine microbiomes of most participants differed significantly during at least one post-treatment week relative to pre-treatment composition. Differential abundance analysis revealed many significantly different taxa; several were not among the most abundant.
conclusionsMH treatment did not sterilize the bladder nor did it eliminate uropathogens. Instead, it uniquely altered each participant's voided urine microbiome. To understand the mechanism of action, researchers should look beyond suspected uropathogens and consider the participant and the rest of their urobiome.
Indexed as
Identifiers
41317299What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.